Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Orexo AB (ORX.ST)
Uppsala, AB, SE
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.30% | +2.81% | +8.70% | -27.30% | -20.54% | -36.83% | +31.41% | +98.26% | -48.10% | -58.08% | -77.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-95.6% Q1'26: -96.6% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+36.3% ★ Q1'26: -728.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-1,076.9% Q1'26: -668.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-1,357.3% Q1'26: -1,498.0% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%-501.3% Q1'26: +2,066.2% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.5% Q1'26: +14.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-1.72× Q1'26: -0.03× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
643.34M
est: 608.76M (+5.7%)
|
705.80M
est: 694.27M (+1.7%)
|
643.70M
est: 624.93M (+3.0%)
|
783.10M
est: 800.50M (-2.2%)
|
844.80M
est: 848.58M (-0.4%)
|
663.60M
est: 660.28M (+0.5%)
|
565.00M
est: 566.50M (-0.3%)
|
624.30M
est: 627.55M (-0.5%)
|
638.80M
est: 615.20M (+3.8%)
|
590.00M
est: 587.50M (+0.4%)
|
26.00M
est: 508.00M (-94.9%)
|
26.00M
26.00M – 26.00M
-94.9% YoY
|
27.00M
27.00M – 27.00M
+3.8% YoY
|
31.00M
31.00M – 31.00M
+14.8% YoY
|
| EBITDA |
-88.25M
est: -33.90M (-160.3%)
|
80.80M
est: -38.66M (+309.0%)
|
57.60M
est: -34.80M (+265.5%)
|
110.30M
est: -44.57M (+347.4%)
|
288.40M
est: -47.25M (+710.3%)
|
16.80M
est: -36.77M (+145.7%)
|
-141.30M
est: -31.54M (-347.9%)
|
-73.90M
est: -34.94M (-111.5%)
|
-22.10M
est: -160.41M (+86.2%)
|
58.60M
est: -153.19M (+138.3%)
|
-285.90M
est: -132.46M (-115.8%)
|
-6.78M
-6.78M – -6.78M
+94.9% YoY
|
-7.04M
-7.04M – -7.04M
-3.8% YoY
|
-8.08M
-8.08M – -8.08M
-14.8% YoY
|
| EBIT |
-180.60M
est: -119.57M (-51.0%)
|
59.40M
est: -136.37M (+143.6%)
|
36.80M
est: -122.75M (+130.0%)
|
108.70M
est: -157.23M (+169.1%)
|
247.40M
est: -166.68M (+248.4%)
|
-22.10M
est: -129.69M (+83.0%)
|
-194.30M
est: -111.27M (-74.6%)
|
-142.60M
est: -123.26M (-15.7%)
|
-99.10M
est: -239.78M (+58.7%)
|
-130.60M
est: -228.98M (+43.0%)
|
-352.90M
est: -198.00M (-78.2%)
|
-10.13M
-10.13M – -10.13M
+94.9% YoY
|
-10.52M
-10.52M – -10.52M
-3.8% YoY
|
-12.08M
-12.08M – -12.08M
-14.8% YoY
|
| Net Income |
-197.99M
est: -193.11M (-2.5%)
|
29.00M
est: 22.58M (+28.4%)
|
23.20M
est: 20.35M (+14.0%)
|
137.90M
est: 147.24M (-6.3%)
|
219.10M
est: 268.48M (-18.4%)
|
-84.40M
est: -115.29M (+26.8%)
|
-223.50M
est: -197.49M (-13.2%)
|
-177.60M
est: -153.20M (-15.9%)
|
-128.30M
est: -97.08M (-32.2%)
|
-203.00M
est: -117.73M (-72.4%)
|
-129.80M
est: -94.53M (-37.3%)
|
-312.67M
-312.67M – -312.67M
-230.8% YoY
|
-249.65M
-249.65M – -249.65M
+20.2% YoY
|
-268.01M
-268.01M – -268.01M
-7.4% YoY
|
| SGA |
439.03M
est: 386.87M (+13.5%)
|
402.20M
est: 441.22M (-8.8%)
|
286.60M
est: 397.14M (-27.8%)
|
358.10M
est: 508.72M (-29.6%)
|
331.50M
est: 539.28M (-38.5%)
|
389.40M
est: 419.61M (-7.2%)
|
431.90M
est: 360.01M (+20.0%)
|
401.30M
est: 398.81M (+0.6%)
|
369.50M
est: 911.72M (-59.5%)
|
357.00M
est: 870.67M (-59.0%)
|
125.30M
est: 752.85M (-83.4%)
|
38.53M
38.53M – 38.53M
-94.9% YoY
|
40.01M
40.01M – 40.01M
+3.8% YoY
|
45.94M
45.94M – 45.94M
+14.8% YoY
|
| EPS |
-5.74
est: -5.60 (-2.4%)
|
0.84
est: 0.66 (+28.2%)
|
0.67
est: 0.59 (+13.5%)
|
3.99
est: 4.27 (-6.6%)
|
6.33
est: 7.79 (-18.7%)
|
-2.45
est: -3.35 (+26.8%)
|
-6.51
est: -5.73 (-13.6%)
|
-5.17
est: -4.45 (-16.3%)
|
-3.73
est: -2.80 (-33.0%)
|
-5.89
est: -3.40 (-73.2%)
|
-3.75
est: -2.73 (-37.4%)
|
-9.03
-9.03 – -9.03
-230.8% YoY
|
-7.21
-7.21 – -7.21
+20.2% YoY
|
-7.74
-7.74 – -7.74
-7.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 20.0K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nikolaj Sorensen | President & Chief Executive Officer | 7M | male |
| Edward Kim | Senior VP & Chief Medical Officer | — | — |
| Fredrik Jarrsten | Executive Vice President & Chief Financial Officer | — | male |
| Jesper Lind | Advisor | — | male |
| Lena Wange | Investor Relations & Communications Director | — | — |
| Lisa Moore | Senior Vice President of Products & Portfolio Strategy | — | female |
| Cecilia Coupland | Senior Vice President & Head of Operations | — | female |
| Robert Ronn | Senior Vice President and Head of R&D | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ORX.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
